Compare
Tectonic Therapeutic, Inc. vs Coherus Oncology, Inc. vs Lexeo Therapeutics, Inc. vs Voyager Therapeutics, Inc.
| Latest fiscal year | Tectonic Therapeutic, Inc. TECX | Coherus Oncology, Inc. CHRSRevenue covers only part of its income (partial revenue) | Lexeo Therapeutics, Inc. LXEO | Voyager Therapeutics, Inc. VYGR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $40.37M |
| Revenue growth (YoY) | n/a | n/a | n/a | -49.5% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | -326.6% |
| Net margin | n/a | n/a | n/a | -296.5% |
| Net income | -$74.15M | $168.02M | -$99.96M | -$119.72M |
| EPS (Diluted) | -$4.05 | $1.43 | -$1.86 | -$2.04 |
| Operating cash flow | -$60.08M | -$138.51M | -$98.56M | -$132.47M |
| Free cash flow | -$60.29M | n/a | -$98.96M | -$135.06M |
| Cash & equivalents | $253.80M | $88.88M | $63.00M | $65.30M |
| Total assets | $261.04M | $258.34M | $268.69M | $252.28M |
| Total liabilities | $9.71M | $197.33M | $22.02M | $56.20M |
| Shareholders' equity | $251.33M | $61.01M | $246.67M | $196.08M |
| Return on year-end equity | -29.5% | 275.4% | -40.5% | -61.1% |
| Shares outstanding | 18.74M | 121.15M | 73.00M | 59.05M |
Revenue, most recent five fiscal years
| Fiscal year | Tectonic Therapeutic, Inc. | Coherus Oncology, Inc. | Lexeo Therapeutics, Inc. | Voyager Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $654.0K Ended 2022-12-31 | $40.37M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $80.00M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $250.01M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $40.91M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $37.41M Ended 2021-12-31 |